[{"address1": "828 Winter Street", "address2": "Suite 300", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "857-524-2466", "website": "https://xiliotx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 64, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rene  Russo BCPS, Pharm.D.", "age": 49, "title": "President, CEO & Director", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 966228, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Frankenfield", "age": 42, "title": "CFO & COO", "yearBorn": 1982, "fiscalYear": 2024, "totalPay": 786196, "exercisedValue": 0, "unexercisedValue": 260}, {"maxAge": 1, "name": "Dr. Katarina  Luptakova M.D.", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 661890, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin M. Brennan", "age": 54, "title": "Senior Vice President of Finance & Accounting", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Uli  Bialucha Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Caroline  Hensley", "title": "Chief Legal Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott  Coleman Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.6783, "open": 0.69, "dayLow": 0.6721, "dayHigh": 0.7314, "regularMarketPreviousClose": 0.6783, "regularMarketOpen": 0.69, "regularMarketDayLow": 0.6721, "regularMarketDayHigh": 0.7314, "payoutRatio": 0.0, "beta": 0.019, "forwardPE": -1.2068965, "volume": 882274, "regularMarketVolume": 882274, "averageVolume": 1255796, "averageVolume10days": 1401340, "averageDailyVolume10Day": 1401340, "bid": 0.5066, "ask": 0.8751, "bidSize": 2, "askSize": 2, "marketCap": 36247608, "fiftyTwoWeekLow": 0.62, "fiftyTwoWeekHigh": 1.7, "priceToSalesTrailing12Months": 3.9085193, "fiftyDayAverage": 0.7756, "twoHundredDayAverage": 0.8847, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -44961408, "profitMargins": 0.0, "floatShares": 25003071, "sharesOutstanding": 51782300, "sharesShort": 1219174, "sharesShortPriorMonth": 562279, "sharesShortPreviousMonthDate": 1744675200, "dateShortInterest": 1747267200, "sharesPercentSharesOut": 0.0235, "heldPercentInsiders": 0.28177, "heldPercentInstitutions": 0.40575, "shortRatio": 0.5, "shortPercentOfFloat": 0.0344, "impliedSharesOutstanding": 51782300, "bookValue": 0.207, "priceToBook": 3.3816423, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -54303000, "trailingEps": -0.65, "forwardEps": -0.58, "enterpriseToRevenue": -4.848, "enterpriseToEbitda": 0.814, "52WeekChange": -0.33962262, "SandP52WeekChange": 0.119305134, "quoteType": "EQUITY", "currentPrice": 0.7, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "totalCash": 89073000, "totalCashPerShare": 1.72, "ebitda": -55259000, "totalDebt": 7864000, "quickRatio": 1.912, "currentRatio": 1.956, "totalRevenue": 9274000, "debtToEquity": 73.495, "revenuePerShare": 0.142, "returnOnAssets": -0.38211, "returnOnEquity": -2.97836, "grossProfits": 9274000, "freeCashflow": 19131376, "operatingCashflow": 21102000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -4.7273, "financialCurrency": "USD", "symbol": "XLO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Xilio Therapeutics, Inc.", "marketState": "CLOSED", "corporateActions": [], "exchange": "NMS", "messageBoardId": "finmb_365333564", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 3.19917, "regularMarketPrice": 0.7, "shortName": "Xilio Therapeutics, Inc.", "postMarketTime": 1749252715, "regularMarketTime": 1749240000, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1634909400000, "postMarketChangePercent": -0.0142881, "postMarketPrice": 0.6999, "postMarketChange": -0.000100017, "regularMarketChange": 0.0217, "regularMarketDayRange": "0.6721 - 0.7314", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1255796, "fiftyTwoWeekLowChange": 0.07999998, "fiftyTwoWeekLowChangePercent": 0.12903222, "fiftyTwoWeekRange": "0.62 - 1.7", "fiftyTwoWeekHighChange": -1.0, "fiftyTwoWeekHighChangePercent": -0.58823526, "fiftyTwoWeekChangePercent": -33.96226, "earningsTimestamp": 1746703800, "earningsTimestampStart": 1754479858, "earningsTimestampEnd": 1754911858, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.65, "epsForward": -0.58, "fiftyDayAverageChange": -0.07560003, "fiftyDayAverageChangePercent": -0.09747296, "twoHundredDayAverageChange": -0.18470001, "twoHundredDayAverageChangePercent": -0.20877135, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-22", "averageAnalystRating": "1.0 - Strong Buy", "cryptoTradeable": false, "displayName": "Xilio Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-06-07"}]